Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

May 15, 2025 09:00 ET | Source: GT Biopharma, Inc.

GT Biopharma Appoints New Member to its Board of Directors

SAN FRANCISCO, CALIFORNIA, May 15, 2025 (GLOBE NEWSWIRE) -- GT Biopharma, Inc. (the “Company”) (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics...
August 14, 2024 16:05 ET | Source: GT Biopharma, Inc.

GT Biopharma Reports Second Quarter 2024 Financial Results and Provides Corporate Update

GTB-3650 TriKE® Phase 1 trial initiation expected in 2H 2024; initial clinical data expected in 1H 2025GTB-5550 TriKE® IND submission for treatment of B7H3 positive solid tumors expected in 1H...
March 26, 2024 17:00 ET | Source: GT Biopharma, Inc.

GT Biopharma Reports Fourth Quarter and Full-Year 2023 Financial Results

Remain in active dialogue with the FDA regarding IND clearance for GTB-3650, a 2nd generation nanobody TriKE® for treatment of CD33+ leukemiaPhase 1 trial with GTB-3650 anticipated to start in 2H...
November 03, 2022 09:00 ET | Source: GT Biopharma, Inc.

GT Biopharma to Present New Data on Novel Dual-Antigen Targeting Approach Against AML at Upcoming 2022 ASH Annual Meeting

BRISBANE, CALIFORNIA, Nov. 03, 2022 (GLOBE NEWSWIRE) -- GT Biopharma, Inc. (the “Company” or “GTB”) (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing innovative...
October 31, 2022 17:15 ET | Source: GT Biopharma, Inc.

GT Biopharma Reports Third Quarter Fiscal 2022 Financial Results and Business Update

Announced two poster presentations at the Society for Immunotherapy of Cancer’s 37th Annual Meeting (SITC 2022)$20.8 million in cash, cash equivalents and short-term investments as of September 30,...